User-Friendly Methylation of Aryl and Vinyl Halides and Pseudohalides with DABAL-Me3
作者:Thea Cooper、Andrew Novak、Luke D. Humphreys、Matthew D. Walker、Simon Woodward
DOI:10.1002/adsc.200505405
日期:2006.4
An extremely technically simple cross-methylation of aryl and vinylhalides and pseudohalides using an air-stable adduct of trimethylaluminium with a Pd(0) catalyst supported by commercially available biarylphosphines gives excellent yields of methylated products (mainly >95%). Reactions can be run with either 0.5 mol % catalyst or without requiring the exclusion of atmospheric oxygen or the drying
HETEROCYCLIC COMPOUND AND MEDICINAL APPLICATION THEREOF
申请人:Japan Tobacco, Inc.
公开号:EP1953147A1
公开(公告)日:2008-08-06
The present invention aims at providing a novel heterocyclic compound having HCV entry inhibitory activity and the pharmaceutical use thereof. The present invention provides a therapeutic agent for hepatitis C comprising a heterocyclic compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein Q1 is -N=, etc., Q2 is -N-, etc., Q3 is -N=, etc., Q4 is -N-, etc., Q5 is -N-, etc., R1 is a hydrogen atom, etc., R2 is a hydrogen atom, etc., ring A is a monocyclic aryl group optionally having substituent(s), etc., and ring B is a monocyclic aryl group optionally having substituent(s), etc.
The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I):
wherein R
1
, R
2
, R
3
, R
4
, and G are defined as herein, a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral used and for external application, which each contains the said compound as an active ingredient.
COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
申请人:GLOBAL BLOOD THERAPEUTICS, INC.
公开号:US20160031865A1
公开(公告)日:2016-02-04
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.